Agilent Technologies, Inc. · NYSE:A
Agilent Technologies — Q2 2017 Earnings Presentation
10 slides from Agilent Technologies's earnings presentation, May 2017
Slide 1: Agilent Technologies Q2'17 Results Presentation
Agilent Technologies Q2'17 Results Presentation
Slide 2: Safe Harbor
Safe Harbor This presentation contains forward-looking statements (including, without limitation, information and future guidance on the company’s goals, priorities, revenues, operating profit and operating margin, growth opportunities, customer service and innovation plans, new product introduction
Slide 3: Agilent Results Q2'17
Agilent Results Q2'17 Scale and leading technology across Analytical Laboratories and Clinical & Dx markets Q2'17 Financial Metrics Q2'17 Headlines • Revenues: $1.10B, +8.7% y/y core(1)(2),+8.1% • Growth: Strong pick-up in Chemical & Energy reported (+0.3% M&A, -0.9% FX). Core growth with results in
Slide 4: Life Sciences & Applied Markets Group (LSAG)
Life Sciences & Applied Markets Group (LSAG) • Strong core revenue growth across regions Instrumentation and Informatics for Analytical Laboratories with strength in Asia and Europe. Chem & Energy, Environmental and Pharma led growth, with strong momentum in most analytical platforms. • Operating Ma
Slide 5: Agilent Cross Lab Group (ACG)
Agilent Cross Lab Group (ACG) Analytical Laboratory • Continued momentum with growth across Consumables and Services all end markets and regions led by expansion in Asia. Particular strength in Enterprise Services and Consumables. • Operating Margin in the quarter was 21.6%((2), up 10 bps versus las
Slide 6: Diagnostics and Genomics Group (DGG)
Diagnostics and Genomics Group (DGG) Pathology, Genomics, and • Solid growth performance across markets Nucleic Acid Manufacturing and regions led by strength in Pathology, Companion Diagnostics and Nucleic Acid Solutions. China and Japan led regional gains. • Operating Margin for the quarter was 24
Slide 7: Growth in a $50B Market – Q2'17 Results by End Market
Growth in a $50B Market – Q2'17 Results by End Market Robust growth led by pick-up in Chemical/Energy plus ongoing Pharma, Diagnostics/Clinical and Environmental momentum. Analytical Laboratory End Markets Agilent Revenue by End Market (1) Q2'17 revenues: +9% y/y on core(2) basis Pharma & Biotec
Slide 8: Profitable Growth Plan
Agilent Profitable Growth Plan Recent Actions Delivering on “Agile Agilent” Initiatives • Multi-year program to increase efficiency and customer focus. • Operating Margin up year-over-year – 9th consecutive quarter. • Launched eRenewals, a first-of-its-kind program enabling paperless renewals of c
Slide 9: Strategy to Win
Agilent Strategy to Win Creating shareholder value Above Market Growth • Win enterprise lab-wide services & consumables - CrossLab • Accelerate bio-pharma penetration • Drive adoption of clinical genomics applications Aggressively expand operating margins • FY17 adjusted Operating Margin guidanc
Slide 10: Q3'17 and FY17 Guidance and Forward-looking Considerations
Q3’17 and FY17 Guidance and Forward-looking Considerations Based on April 28, 2017 Exchange Rates FY17 Guidance • Revenue: $4.36B - $4.38B: growth at mid-point 5.0% core(4), 4.0% reported (1) (+0.2% M&A, -1.2% FX) • Operating Margin: 21.2% at mid-point or 21.5%(3) when adjusted for $12M in Keysight